NCT06873334 · Phase 2 · ACTIVE NOT RECRUITING

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

This trial tests SKY-0515, a daily pill, in adults with Huntington's disease. Researchers want to see whether it lowers a harmful protein tied to the disease and whether symptoms improve, compared with a placebo. It is a Phase 2 trial: testing early safety and whether it works, not yet proven or approved.

You may qualify if

  • You must be 25 years or older.
  • You must have Huntington's Disease confirmed through genetic testing, with a specific gene change (CAG repeat of 40 or more).
  • Total Functional Capacity (TFC) score of 10 or more).
  • Total Motor Score (TMS) of 6 or more).
  • Independence Score (IS) of 70 or more).
  • Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug.
  • Men must agree to use birth control during the study and for 90 days after the last dose.
  • You must agree to sign a consent form and follow the study's rules and schedule.

You're excluded if

  • You have other serious health problems or brain/spinal issues that could interfere with the study or make procedures unsafe.
  • You have a condition that interferes with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI.
  • You have cancer, except for some types of skin cancer, or a history of cancer in the last five years.
  • You have severe allergies or have reacted badly to similar drugs in the past.
  • You are taking medications or treatments that might interfere with the study.
  • You've been in another study or taken experimental drugs in the last two months (or longer for some drugs).
  • You have had any kind of gene therapy.
  • You have a history of suicidal thoughts, severe depression, or have attempted suicide in the past year.
  • Your liver function tests show significant abnormalities.
  • You have tested positive for hepatitis B, hepatitis C, or HIV.
  • You are pregnant, breastfeeding, or planning to become pregnant during the study.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-05-01

View full record on ClinicalTrials.gov

All APOE4 clinical trials